NextCure, Inc.

Avere Therapeutics' lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy

The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.

SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage bi

PRN_FinancialWrapper

Detailed price information for Nextcure Inc (NXTC-Q) from The Globe and Mail including charting and trades.

--NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled" LAIR-1 Ag

--NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled" Remodeling the

Nextcure's solid footing should sustain it despite Eli Lilly's decision to walk away from an R&D pact.